Keeping you up to date with all the Lymphoma Team news

Jane our Christie Hero! (July 2018)

As part of the Christie celebrating the 70th anniversary of the NHS, for 70 days 70 individuals have been nominated by staff or patients as a 'Christie hero'.

We are pleased to announce that our very own Jane Gibson-Advanced Nurse Practitioner was nominated by Nigel Billings, a patient at The Christie. Nigel said “Jane was my Lymphoma Nurse and my first point of contact. Her support has helped me through this chapter of my life. She is a very special person to me.”

Within the last 12 months Jane has transitioned from a Clinical Nurse Specialist to an Advanced Nurse Practitioner and is excelling in her new role within the team.

Well done Jane, very well deserved!

Triumph at Royal College awards for Professor Illidge (July 2018)

Professor Tim Illidge, Professor of Targeted Therapy and Oncology and three senior researchers based at The Christie have won prestigious honours from the Royal College of Radiologists (RCR).

Professor Illidge, received the RCR Gold Medal, the highest honour the college can award and made in recognition of his ‘enormous national and international contribution to clinical oncology’. 

Prof Illidge is the first Manchester-based recipient of the award since Professor Ralston Paterson in 1966. Prof Paterson was a world-leading authority on treating cancer with radiotherapy and gave his name to the building on Wilmslow Road in Withington which was badly damaged by fire in April 2017.

Prof Illidge, who lives in Disley, is head of the division of cancer services at The University of Manchester and oversees a large number of academic staff. He said: “The medal came as a tremendous surprise but of course I’m really honoured and humbled to receive it.

“Awards such as this are always the result of a big team effort so it’s recognition of all the hard work my colleagues at The University of Manchester and The Christie have put in. I am thrilled that three of us from Manchester were honoured at the awards ceremony which shows that we are recognised as being at the forefront of clinical oncology in the UK.

“There have been very few oncologists to have won the gold medal in the last 50 years and it is great that Manchester has got this recognition again.”

The awards took place at the RCR’s annual Admission of Fellows ceremony at Westminster Central Hall in London.

The lymphoma team congratulate Tim and his colleagues for this fantastic achievement!

Cupcake day for Alzheimers society (June 2018)

In June the clinical trial co-ordinators held a cake sale to raise money for the Alzheimer’s Society.

They raised £65.00 which with gift aid will come to £81.25!

As it was such a success we have decided to hold a charity cake sale every couple of months for different charities of choice.

Well done to everyone who baked the extremely tasty cakes and thank you to each member of staff who donated money for a brilliant cause!


First in the UK (March 2018)

In March the lymphoma team were the first in the UK to recruit two new patients with follicular lymphoma into the clinical trial ReBel. This new trial is to see how well lenalidomide and rituximab work with or without bendamustine in people with relapsed follicular lymphoma. For further information about this trial please click here.

A Christmas gift (Dec 2017)

Clinical trial patient Nigel and his wife Julie presented Dr Kim Linton with a beautiful hand crafted advent calendar for The Lymphoma Team just in time for advent!

We are delighted with the thoughtful gift which Julie has been making since August and it will have pride of place in our office for everyone to enjoy. Thank you to Nigel and Julie and a Merry Christmas to all our patients and their families!

Winner! (Nov 2017)

In November Professor Radford was announced as winner of the ‘Lifetime Achievement’ category at the Greater Manchester Clinical Research Awards. He has led many practice-changing trials in lymphoma and is an internationally recognised leader in the field so as a team we are extremely pleased he was recognised in this way.

Professor Radford was humbled and regarded the award as ‘flying the flag for all the high impact clinical research going on at the Christie and our partners, including other trusts, The University of Manchester and Cancer Research UK'.

First in the world (July 2017)

In July we became the first site in the world to open the new CTCL chart review study. This study looks at real-world treatment patterns and outcomes in relapsed/refractory cutaneous T-cell lymphoma (CTCL).

Welcome Chiara (June 2017)

We give a warm welcome to our new research nurse Chiara Dallatorre who started on the team in June 2017. Chiara is an experienced haematology nurse who has previously worked for Blackpool Victoria Hospital and we are sure she will make a great addition to our research team.


Lead Authors (June 2017)

In January Professor Radford and Dr Gibb were named as lead authors on a Pfizer abstract to be presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland in June 2017.

Professor Radford joins AOL (May 2017)

Professor John Radford has recently been invited to join the editorial board of the AOL (Annals of Lymphoma) which is a rising high quality electronic journal, openly distributed worldwide relating to lymphoma research.


  • We are very happy to announce that on the 17th November our team were named winners of Research Team Of The Year at the Greater Manchester Clinical Research Awards 2016!

  • On the 22nd of October 2016 The BREVITY trial along with our other projects ADAPT and BARD were presented at ISHL (International Symposium of Hodgkin lymphoma) in Cologne by Professor Radford and Dr Adam Gibb.

  • In November our team was the 1st recruiter in the UK for the SGN35.023 trial. This study looks at comparing treatment with the combination of rituximab and bendamustine chemotherapy against the combination of rituximab and bendamustine with added brentuximab.

  • The Lymphoma Group were the 1st recruiter in the world for the BI 1206 CRUK clinical trial. BI 1206 is a type of biological therapy called an antibody. It works by recognising and attaching to a particular protein called CD32b. This protein is found on some cancer cells in some types of lymphoma and leukaemia. Laboratory studies show that by blocking the CD32b protein BI 1206 could stop cancer cells from growing and dividing. Researchers want to find out if BI 1206 can help people with B cell non Hodgkin lymphoma and chronic lymphocytic leukaemia (CLL).

  • Our team has now been re-designated as a Bloodwise TAP (Trials Acceleration Programme) Centre, making us 1 of 13 centres nationally.

  • Our clinical research nurse Andrea Whitmore successfully completed a skin biopsy course and will now be carrying out biopsies for our lymphoma patients when required. This will be highly beneficial as it prevents the need to use other services, reduces patient waiting times and will be more convenient to our patients overall. Well done Andrea!

  • The Lymphoma Group were the UK's top recruiter for the Polatuzumab Vedotin trial (GO29365). This study was looking at Polatuzumab Vedotin in combination with Bendamustine and Rituximab or Obinutuzumab.

  • The Lymphoma Group were the UK's first recruiter and second global recruiter for the JAVELIN Hodgkin lymphoma trial which is a study looking at Avelumab in patients with previously treated advanced stage Hodgkin lymphoma.